期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 31, 期 2, 页码 66-73出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2009.10.010
关键词
-
资金
- Sie Foundation
- Fondation Jerome Lejeune
- National Institute of Child Health and Human Development (NICHD) [HD056235]
Intellectual disability in Down syndrome (DS) ranges from low normal to severely impaired and has a significant impact on the quality-of-life of the individuals affected and their families. Because the incidence of DS remains at approximately 1 in 700 live births and the lifespan is now >50 years, development of pharmacotherapies for cognitive deficits is an important goal. DS is due to an extra copy of human chromosome 21 and has often been considered too complex a genetic abnormality to be amenable to intervention. However, recent successes in rescuing learning/memory impairments in a mouse model of DS suggest that this negative outlook may not be justified. In this contribution, we first review the DS phenotype, chromosome 21 gene content and mouse models' We then discuss recent successes and the remaining challenges in the identification of targets for and preclinical evaluation of potential therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据